source
- Eli Lilly’s $3.8 billion acquisition of AtaiBeckley signals strong backing for psychedelic therapeuticsNovartis and Roche kicked off the second‑quarter earnings season, with other majors such as AstraZeneca, GSK and Biogen slated to follow. The earnings wave highlights continued revenue growth acros…
- Vertex's $10 billion Crinetics buyout draws investor doubts over premium priceVertex was the lone bidder in a planned $10 billion acquisition of Crinetics Pharmaceuticals, a California company that focuses on endocrine medicines. Crinetics currently markets a therapy for a…